Elevance Health stock gets Argus Buy upgrade as 2027 view firms
Published on 11/21/2026 at 10:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst upgrade shapes weekly view
- Argus moved its Elevance Health rating from Hold to Buy on November 18.
- The analyst sees stronger 2027 earnings growth as margin actions gain traction.
- The weekly Xetra close remained lower despite the new bullish rating.
Argus upgraded its rating on Elevance Health from Hold to Buy on Wednesday, November 18. The analyst expects stronger earnings-per-share growth in 2027 as corporate actions to improve operating margins gain traction, according to Markets Insider.
Argus focuses on margin recovery
The upgrade puts the insurer's margin program and its 2027 earnings path at the center of the analyst view. For investors, the key question is whether operating improvements can translate into more durable earnings growth rather than a short-lived improvement in reported results.
Elevance Health stock traded at 359.65 euros on Lang & Schwarz at 10:45 CET on Saturday, November 21, 2.59 percent below the Xetra close of Friday, November 20. The Xetra close moved from 383.30 euros on Friday, November 13, to 369.20 euros on Friday, November 20, a weekly decline of 3.68 percent, according to Marketscreener.
What investors should watch next
The rating change raises the importance of the next operating update, especially evidence that margin actions are improving the quality of earnings. The weekly decline also shows that the new analyst view has not yet translated into a stronger Xetra close.
Elevance Health stock overview
- Company: Elevance Health
- ISIN: US0367521038
- NYSE ticker: ELV
- Xetra symbol: A58
- Lang & Schwarz quote: 359.65 euros on November 21, 2026, at 10:45 CET
- Xetra close: 369.20 euros on November 20, 2026
- Weekly Xetra change: -3.68 percent from November 13 to November 20, 2026
US market developments can be followed in current market reports.
